Cirrus Therapeutics Announces Strategic Expansion to Singapore and Other Key Updates Supporting its Growth as a Leading Global Ocular Immunology Company

Si Hui Tan, PhD Director, Pipeline and Site Head, Singapore, Cirrus Therapeutics Ying Kai Chan, PhD Chief Executive Officer ...
Ophthalmology Times

FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...
Healio

Study provides multimodal assessment of geographic atrophy precursors

Please provide your email address to receive an email when new articles are posted on . A study presented at Angiogenesis, Exudation, and Degeneration 2024 provided insights on how geographic atrophy ...
Healio

VIDEO: Consider imaging biomarkers, demographic factors in geographic atrophy risk

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
MedPage Today

Geographic Atrophy Lesions in a Cohort with Intermediate AMD

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...